Skip navigation
Skip navigation
A change is coming. Click to see a sneak peek of the new Open Research Repository.

Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future

Request a Copy

link to publisher version

  • Altmetric Citations

Pokorny, Adrian M J; Chin, Venessa; Nagrial, Adnan M; Yip, Desmond; Chantrill, Lorraine

Description

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a lethal disease with a poor 5-year survival. Systemic treatments can be used to control symptoms and prolong life. Cytotoxic chemotherapies are commonly administered, with combination treatments, such as fluorouracil, folinic acid, irinotecan and oxaliplatin (FOLFIRINOX) or nab paclitaxel and gemcitabine showing the largest clinical benefits. Newer genomic classifications of PDAC may provide a rationale for targeted therapies or...[Show more]

dc.contributor.authorPokorny, Adrian M J
dc.contributor.authorChin, Venessa
dc.contributor.authorNagrial, Adnan M
dc.contributor.authorYip, Desmond
dc.contributor.authorChantrill, Lorraine
dc.date.accessioned2020-01-02T03:33:41Z
dc.identifier.issn1444-0903
dc.identifier.urihttp://hdl.handle.net/1885/196459
dc.description.abstractMetastatic pancreatic ductal adenocarcinoma (mPDAC) is a lethal disease with a poor 5-year survival. Systemic treatments can be used to control symptoms and prolong life. Cytotoxic chemotherapies are commonly administered, with combination treatments, such as fluorouracil, folinic acid, irinotecan and oxaliplatin (FOLFIRINOX) or nab paclitaxel and gemcitabine showing the largest clinical benefits. Newer genomic classifications of PDAC may provide a rationale for targeted therapies or immunotherapies, although at present these remain largely experimental. This review discusses the evidence behind the currently used regimens, while introducing the potential future of pancreatic cancer care
dc.format.mimetypeapplication/pdf
dc.language.isoen_AU
dc.publisherWiley
dc.rights© 2018 Royal Australasian College of Physicians
dc.sourceInternal Medicine Journal
dc.titleMetastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future
dc.typeJournal article
local.description.notesImported from ARIES
local.identifier.citationvolume48
dc.date.issued2018
local.identifier.absfor111205 - Chemotherapy
local.identifier.absfor111207 - Molecular Targets
local.identifier.ariespublicationu5234101xPUB260
local.publisher.urlhttps://www.wiley.com/en-gb
local.type.statusPublished Version
local.contributor.affiliationPokorny, Adrian M J, The Kinghorn Cancer Centre
local.contributor.affiliationChin, Venessa, The Kinghorn Cancer Centre, and the Cancer Research Program
local.contributor.affiliationNagrial, Adnan M, Crown Princess Mary Cancer Centre
local.contributor.affiliationYip, Desmond, College of Health and Medicine, ANU
local.contributor.affiliationChantrill, Lorraine, The Kinghorn Cancer Centre, and the Cancer Research Program
local.description.embargo2037-12-31
local.bibliographicCitation.issue6
local.bibliographicCitation.startpage637
local.bibliographicCitation.lastpage644
local.identifier.doi10.1111/imj.13810
local.identifier.absseo920102 - Cancer and Related Disorders
dc.date.updated2019-08-04T08:21:23Z
local.identifier.scopusID2-s2.0-85048359625
CollectionsANU Research Publications

Download

File Description SizeFormat Image
01_Pokorny_Metastatic_pancreatic_ductal_2018.pdf450.17 kBAdobe PDF    Request a copy
Show simple item record


Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  17 November 2022/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator